Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on February 8, 2019, covering events occurring on February 6, 2019. The company is an emerging growth company incorporated in Nevada, headquartered in La Jolla, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
There are no material financial changes reported in this filing. The primary event is the announcement of a scheduled presentation by the company's President and CEO at an industry conference.
Guidance, Outlook, and Management Commentary
On February 6, 2019, the Company issued a press release (Exhibit 99.1) announcing that R.J. Tesi, M.D., President and Chief Executive Officer, will present a company overview at the BIO CEO & Investor Conference. The presentation is scheduled for Monday, February 11, 2019, at 9:15 a.m. Eastern time in the Chelsea Room at the New York Marriott Marquis in New York City. The filing explicitly states that the information contained herein is not deemed "filed" for purposes of Section 18 of the Exchange Act and does not constitute a representation that the information is required by Regulation FD.
Investor Verification Checklist
- Verify the content of the press release attached as Exhibit 99.1 for specific details on the company overview.
- Confirm the date and time of the BIO CEO & Investor Conference presentation (February 11, 2019, 9:15 a.m. ET).
- Review the company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains no financial metrics.